- The University of Texas Health Science Center at San Antonio (UT Health San Antonio) announces the successful launch of Pluvicto, a radiopharmaceutical used to treat patients with advanced metastatic prostate cancer. Approved by the U.S. Food and Drug Administration in March of 2022, Pluvicto is a novel targeted molecular therapy that delivers radiation treatment […]
- Contact: Eileen Teves, 210-450-7239, tevese@uthscsa.edu SAN ANTONIO, Oct. 6, 2023 – The University of Texas Health Science Center at San Antonio (UT Health San Antonio) announces the successful launch of Pluvicto, a radiopharmaceutical used to treat patients with advanced metastatic prostate cancer. Approved by the U.S. Food and Drug Administration in March of 2022, Pluvicto […]
- The UT Health San Antonio Mays Cancer Center, along with Josephine Taverna, MD, Department of Medicine, Division of Hematology and Oncology, and Tim Hui-Ming Huang, PhD, chair, Department of Molecular Medicine, were mentioned in this article. Read More
- The UT Health San Antonio Mays Cancer Center, along with Josephine Taverna, MD, Department of Medicine, Division of Hematology and Oncology, and Tim Hui-Ming Huang, PhD, chair, Department of Molecular Medicine, were mentioned in this article. Read More
- Thank you for powering UT Health San Antonio! You play an important role in fulfilling the promise we hold to make tomorrow a brighter, healthier day. Your partnership is what fuels our journey in advancing our missions and making a positive and significant difference in the communities we serve. All of us, working together, […]
- Three decades after discoveries linking mutations in the BRCA1 gene to breast and ovarian cancer susceptibility, research led by Mays Cancer Center at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has pinpointed the molecular mechanism by which a large portion of these mutations cause cancers in women. The […]
- Contact: Steven Lee, (210) 450-3823, lees22@uthscsa.edu SAN ANTONIO, Oct. 6, 2023 – Three decades after discoveries linking mutations in the BRCA1 gene to breast and ovarian cancer susceptibility, research led by Mays Cancer Center at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has pinpointed the molecular mechanism by […]
- Sixteen faculty and staff leaders from across the institution recently completed the nine-month Leadership Excellence for Academic Professionals program. LEAP graduation on Sept. 22 was marked by the eight-member teams’ presentations to a panel of senior leaders. In those, the graduates summarized findings from projects in which they expanded their leadership knowledge and practical skills […]
- Research led by Mays Cancer Center at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has discovered that altering certain molecular interactions could yield new strategies for treating prostate cancer and related diseases. The study focuses on androgen receptors (AR), which are protein molecules that help direct the development […]
- Contact: Steven Lee, (210) 450-3823, lees22@uthscsa.edu SAN ANTONIO, Oct. 5, 2023 – Research led by Mays Cancer Center at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) has discovered that altering certain molecular interactions could yield new strategies for treating prostate cancer and related diseases. The study focuses on […]
